Abstract:Objective: To investigate the effect of Xiaoke Wan and Xuezhikang on mannan binding lectin (MBL) in patients with type2 diabetes mellitus and hyperlipidemia. Method: Eighty patients with type2 diabetes mellitus combined with hyperlipidemia were randomly divided into observation group and control group (n=40 each). Observation group was firstly received Xiaoke Wan, 10 pills, before breakfast and lunch. Patients in observation group were also orally received Xuezhikang capsules, 2 capsules, bid. Control group was firstly received glibenclamide tablet, 2.5 mg before breakfast and lunch. Patients in control group were also orally received simvastatin, 20 mg daily. The amount of Xiaoke Wan and glibenclamide were adjusted according to blood glucose level in the two groups. The treatment course of the two groups lasted 12 weeks. Additional 20 normal persons were grouped as the healthy control group. Fasting blood glucose (FBG), level of postprandial 2 h blood glucose (2 hPG), glycated hemoglobin (HbAlc), total cholesterol (TC), triglyceride (TG), low density lipoprotein chotesterol(LDL-C) and high density lipoprotein chotesterol(HDL-C) and MBL were tested before and after treatment. Result: After treatment, FBG and 2 h PBG in the two groups were significantly lower than those before treatment, but there was no significant difference between the two groups. After treatment, HbA1c in the two groups was decreased significantly, and that in observation group decreased more (P<0.05). After treatment, there was no significant difference in blood glucose level between the two groups, LDL-C in control group was still higher than normal control group (P<0.05). After treatment, MBL in observation group was (0.71±0.25) mg·L-1, which was lower than that in normal control group (P<0.05), but significantly higher than that before treatment (P<0.01). MBL in control group was (0.40±0.21) mg·L-1, which was lower than that before treatment. Conclusion: Xiaoke Wan combined with Xuezhikang can effectively control blood glucose and lipids in the patients with type2 diabetes mellitus and hyperlipidemia, raise MBL level, and help to control inflammation.
